期刊
JOURNAL OF BONE AND MINERAL RESEARCH
卷 37, 期 12, 页码 2663-2677出版社
WILEY
DOI: 10.1002/jbmr.4716
关键词
PARATHYROID-RELATED DISORDERS; DISORDERS OF CALCIUM; PHOSPHATE METABOLISM; CELL; TISSUE SIGNALING; ENDOCRINE PATHWAYS; DISORDERS OF CALCIUM; PHOSPHATE METABOLISM
资金
- Takeda
- Amolyt
- Ascendis
- Calcilytix
Hypoparathyroidism is a rare disorder characterized by low calcium levels due to decreased parathyroid hormone. Neck surgery is the most common cause. Conventional therapy includes calcium and vitamin D analogues, but it has limitations. Parathyroid hormone replacement therapy may be beneficial for unsatisfactory cases.
Hypoparathyroidism (HypoPT) is a rare disorder characterized by hypocalcemia in the presence of a low or inappropriately normal parathyroid hormone level. HypoPT is most commonly seen after neck surgery, which accounts for approximately 75% of cases, whereas approximately 25% have HypoPT due to nonsurgical causes. In both groups of patients, conventional therapy includes calcium and active vitamin D analogue therapy aiming to maintain serum calcium concentration in the low normal or just below the normal reference range and normalize serum phosphorus, magnesium concentrations, and urine calcium levels. The limitations of conventional therapy include wide fluctuations in serum calcium, high pill burden, poor quality of life, and renal complications. Parathyroid hormone (PTH) replacement therapy may improve the biochemical profile in those in whom conventional therapy proves unsatisfactory. Based on a systematic review and meta-analysis of the literature, the panel made a graded recommendation suggesting conventional therapy as first line therapy rather than administration of PTH (weak recommendation, low quality evidence). When conventional therapy is deemed unsatisfactory, the panel considers use of PTH. Because pregnancy and lactation are associated with changes in calcium homeostasis close monitoring is required during these periods, with appropriate adjustment of calcium and active vitamin D analogue therapy to ensure that serum calcium remains in the mid to low normal reference range in order to avoid maternal and fetal complications. Emerging therapies include molecules with prolonged PTH action as well as different mechanisms of action that may significantly enhance drug efficacy and safety. (c) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据